Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
Zefei Jiang(Chinese PLA General Hospital), Wei Li(Jilin University), Xichun Hu(Fudan University Shanghai Cancer Center), Qingyuan Zhang(Third Affiliated Hospital of Harbin Medical University), Tao Sun(Liaoning Cancer Hospital & Institute), Shude Cui(Henan Cancer Hospital), Shusen Wang(Peking University Shenzhen Hospital), Quchang Ouyang(Hunan Cancer Hospital), Yongmei Yin(Jiangsu Province Hospital), Cuizhi Geng(Hospital of Hebei Province), Zhongsheng Tong(Tianjin Medical University Cancer Institute and Hospital), Ying Cheng(Jilin Province Tumor Hospital), Yueyin Pan(Anhui Provincial Hospital), Yuping Sun(Jinan Central Hospital), Hong Wang(Third Hospital of Nanchang), Tao Ouyang(Peking University), Kangsheng Gu(First Affiliated Hospital of Anhui Medical University), Jifeng Feng(Jiangsu Cancer Hospital), Xiaojia Wang(Zhejiang Cancer Hospital), Shubin Wang(Sun Yat-sen University), Tianshu Liu(The First Affiliated Hospital, Sun Yat-sen University), Jinghua Gao(Cangzhou Central Hospital), Massimo Cristofanilli, Zhiqiang Ning(Shenzhen Chipscreen Biosciences Co.), Xianping Lu(Shenzhen Chipscreen Biosciences Co.)
Cited by 266
Abstract
Related Papers
No related papers found
Powered by citation graph analysis